COVID-19

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

4 months ago

Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

- 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead's Setting the P.A.C.E. Initiative -FOSTER…

4 months ago

Early Pulmonary Fibrosis Detection Holds the Key to Better Health Outcomes for Canadians Living with COVID-19 and Rheumatoid Arthritis

Canadians who have had COVID-19, and other chronic diseases, are experiencing Pulmonary Fibrosis (PF) at significantly higher rates than others,…

4 months ago

Catheter Precision, Inc. (NYSE American:VTAK) Announces the First Use of VIVO With a Pediatric Patient in Turkey

FORT MILL, SC / ACCESSWIRE / February 28, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a U.S. based…

4 months ago

Moderna to Present at Upcoming Investor Conferences in March 2024

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming…

4 months ago

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

4 months ago

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional…

4 months ago

Silo Wellness Announces Extension of Kaya/NUGL LOI; Annual Filings Delay

Springfield, Oregon--(Newsfile Corp. - February 27, 2024) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo" or "the…

4 months ago

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

4 months ago

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions…

4 months ago